Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Trial watch

Burgeoning oncology pipeline raises questions about sustainability

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Therapeutic area focus of clinical-stage development programmes for new drugs.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Jon Moser or Paul Verdin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information

Indication (XLSX 191 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Moser, J., Verdin, P. Burgeoning oncology pipeline raises questions about sustainability. Nat Rev Drug Discov 17, 698–699 (2018). https://doi.org/10.1038/nrd.2018.165

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing